izpis_h1_title_alt

Optimisation of pyrazolo[1,5-a]pyrimidin-7(4H)-one derivatives as novel Hsp90 C-terminal domain inhibitors against Ewing sarcoma
ID Zajec, Živa (Author), ID Dernovšek, Jaka (Author), ID Distel, Martin (Author), ID Gobec, Martina (Author), ID Tomašič, Tihomir (Author)

.pdfPDF - Presentation file, Download (3,11 MB)
MD5: F5A22E168EBA873144FDBCFED68212AB
URLURL - Source URL, Visit https://www.sciencedirect.com/science/article/pii/S0045206822007179 This link opens in a new window

Abstract
Ewing sarcoma is the second most prevalent paediatric malignant bone tumour. In most cases, it is driven by the fusion oncoprotein EWS::FLI1, which acts as an aberrant transcription factor and dysregulates gene expression. EWS::FLI1 and a large number of downstream dysregulated proteins are Hsp90 client proteins, making Hsp90 an attractive target for the treatment of Ewing sarcoma. In this article, we report a new structural class of allosteric Hsp90 C-terminal domain (CTD) inhibitors based on the virtual screening hit TVS24, which showed antiproliferative activity in the SK-N-MC Ewing sarcoma cell line with an IC$_{50}$ value of 15.9 ± 0.7 µM. The optimised compounds showed enhanced anticancer activity in the SK-N-MC cell line. Exposure of Ewing sarcoma cells to the most potent analogue 11c resulted in depletion of critical Hsp90 client proteins involved in cancer pathways such as EWS::FLI1, CDK4, RAF-1 and IGF1R, without inducing a heat shock response. The results of this study highlight Hsp90 CTD inhibitors as promising new agents for the treatment of Ewing sarcoma.

Language:English
Keywords:cancer, Ewing sarcoma, Hsp90, inhibitor, molecular modelling
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:FFA - Faculty of Pharmacy
Publication status:Published
Publication version:Version of Record
Year:2023
Number of pages:16 str.
Numbering:Vol. 131, art. 106311
PID:20.500.12556/RUL-143238 This link opens in a new window
UDC:615.2:616-006.34
ISSN on article:0045-2068
DOI:10.1016/j.bioorg.2022.106311 This link opens in a new window
COBISS.SI-ID:132438019 This link opens in a new window
Publication date in RUL:09.12.2022
Views:795
Downloads:91
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Bioorganic chemistry
Shortened title:Bioorg. chem.
Publisher:Academic Press.
ISSN:0045-2068
COBISS.SI-ID:25099008 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.

Secondary language

Language:Slovenian
Keywords:Ewingov sarkom, Hsp90, inhibitorji, molekularno modeliranje, maligni tumor kosti, rak, medicina, osteosarkom

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P1-0208
Name:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Funder:ARRS - Slovenian Research Agency
Project number:J1-1717
Name:Razvoj novih zaviralcev Hsp90 s protitumornim delovanjem

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back